Shares of Intercept Pharmaceuticals (ICPT) jumped after the drug maker announced it was changing an ongoing late-stage clinical trial for a drug that treats liver disease.  Patient enrollment in the study has been too slow, so Intercept has changed protocols, drastically cutting the number of patients to be enrolled and lowering the bar for clinical success. Intercept said the changes were based on discussions with the FDA.  (Barrons)